NCT04371458 is a Phase 1/Phase 2 clinical trial of Intraoperative providone-iodine lavage in Stage IVA Thymoma, sponsored by Yale University.

Who is sponsoring NCT04371458?

NCT04371458 is sponsored by Yale University.

What drugs are being tested in NCT04371458?

Interventions in NCT04371458: Intraoperative providone-iodine lavage.

What condition does NCT04371458 study?

NCT04371458 studies Stage IVA Thymoma.

Is NCT04371458 still recruiting?

NCT04371458 is currently withdrawn. Last updated 19 July 2022.

Last reviewed 2022-07-19 · How we verify

NCT04371458

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Study of Extended Thymectomy and Pleural Reductive Surgery (PRS) With Povidone-iodine Pleural Lavage in Patients With Stage IVA Thymic Malignancies

Withdrawn Phase 1/Phase 2 Last updated 19 July 2022

What this trial tests

Phase 1/Phase 2 trial testing Intraoperative providone-iodine lavage in Stage IVA Thymoma. Withdrawn.

Timeline

1 July 2020

Primary endpoint
1 July 2025

1 July 2030

Quick facts

Lead sponsor	Yale University
Phase	Phase 1/Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 July 2020
Primary completion	1 July 2025
Estimated completion	1 July 2030

Drugs / interventions tested

Intraoperative providone-iodine lavage — full drug profile →

Conditions studied

Stage IVA Thymoma — all drugs for Stage IVA Thymoma →

Sponsor

Yale University

Who can join

18 and older, any sex, with Stage IVA Thymoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Progression free survival
Time frame: 5 years
Progression free survival as compared to that of matched patients in a prospectively enrolled international database of thymic malignancies (ITMIG)

Sponsor's own description

To evaluate whether intraoperative pleural lavage with providone-iodine following complete resection and pleural reductive surgery for stage IVA thymoma reduces recurrent rates compared to surgery without providone-iodine lavage

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04371458 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 19 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04371458.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing